Streetbeat News

Stock Prices

BMEA

Biomea Fusion Inc (NASDAQ:BMEA) released preliminary data from its ongoing Phase 1 COVALENT-101 trial, showing initial responses in AML patients with menin-dependent mutations. The analysis showed complete responses in 2 of 5 AML patients. The company also announced the commencement of enrollment for Dose Level 5 to further optimize and explore the potential to improve upon these preliminary results. Despite this, BMEA shares are down 9.71% at $19.44.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 4:09 pm

BABA

NFLX

Steve Weiss, a frequent CNBC contributor, announced live on the network that he has purchased more shares of Alibaba Group (BABA) and Netflix (NFLX).

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 4:07 pm

HRTX

Heron Therapeutics Inc (NASDAQ:HRTX) has announced a cost reduction plan and a corporate restructuring, expected to result in approximately $75 million in cash savings through 2025. The company also announced a private placement of 20.7 million shares at $1.37 per share, with gross proceeds of approximately $30.0 million. HRTX shares are up 9.43% at $1.51 on the last check Monday.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 4:04 pm

ALK

Alaska Air Gr (NYSE:ALK) is set to release its latest quarterly earnings report on Tuesday, 2023-07-25. Analysts estimate an earnings per share (EPS) of $2.70. The company's past performance shows a mixed trend of beating and missing EPS estimates. The company's shares were trading at $54.15 as of July 21, with a 26.23% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 4:03 pm

ASH

Ashland (NYSE:ASH) is set to release its quarterly earnings report on Tuesday, 2023-07-25. Analysts estimate an EPS of $1.35. Last quarter, the company missed EPS by $0.07, resulting in a 9.74% drop in share price. Shares of Ashland were trading at $90.7 as of July 21, with a 52-week return of -13.63%.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 4:03 pm

QNCX

Quince Therapeutics Inc (NASDAQ:QNCX) has agreed to acquire EryDel SpA, a late-stage biotech company. The deal involves a stock-for-stock upfront exchange and potential downstream milestone cash payments. EryDel stockholders will own approximately 16.7% of the combined company and will be entitled to up to $485 million upon achieving development, regulatory, and commercial milestone payments. The transaction is expected to close in Q3 2023. QNCX shares are down 24.10% at $1.20 on the last check Monday.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 4:03 pm

CB

Chubb (NYSE:CB) is set to release its quarterly earnings report on July 25, 2023. Analysts estimate an earnings per share (EPS) of $4.41. The company's past performance shows a pattern of share price changes following earnings announcements. Chubb's shares were trading at $199.81 as of July 21, with a 7.13% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 4:03 pm

UHS

Universal Health Servs (NYSE:UHS) is set to release its latest quarterly earnings report on Tuesday, 2023-07-25. Analysts estimate an earnings per share (EPS) of $2.43. The company's past performance shows a trend of beating EPS estimates, which often leads to an increase in share price. The stock is currently trading at $148.51 and has seen a 35.96% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 4:03 pm

BANC

Banc of California (NYSE:BANC) is set to release its quarterly earnings report on Tuesday, 2023-07-25. Analysts estimate an earnings per share (EPS) of $0.30. The company's past performance shows a mixed trend of meeting or missing EPS estimates, with varying impacts on the share price. The stock is currently trading at $12.79, down 25.71% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 4:02 pm

ONB

Old National (NASDAQ:ONB) is set to release its quarterly earnings report on Tuesday, 2023-07-25, with analysts estimating an EPS of $0.50. The company's past performance shows a trend of beating EPS estimates, which has generally led to an increase in share price. However, the stock has seen a 5.04% decrease over the last 52-week period.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 4:02 pm